Diagnosis and differential assessment of pulmonary arterial hypertension

被引:731
作者
Barst, RJ
McGoon, M
Torbicki, A
Sitbon, O
Krowka, MJ
Olschewski, H
Gaine, S
机构
[1] Columbia Univ Coll Phys & Surg, New York, NY 10032 USA
[2] Mayo Clin, Rochester, MN USA
[3] Inst TB & Lung Dis, Warsaw, Poland
[4] Hop Antoine Beclere, Clamart, France
[5] Univ Clin, Med Clin 2, Giessen, Germany
[6] Univ Coll Dublin, Mater Misericordiae Hosp, Dublin 2, Ireland
关键词
D O I
10.1016/j.jacc.2004.02.032
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Pulmonary arterial hypertension (PAH) is diagnosed by various investigations that are essential for making the diagnosis, and by additional tests to clarify the category of pulmonary hypertension (PH). A diagnostic algorithm can guide the evaluation of PH, but like all guidelines the algorithm can be modified according to specific clinical circumstances. Most patients are diagnosed as the result of an evaluation of symptoms, whereas others are diagnosed during screening of asymptomatic populations at risk. Right heart catheterization (RHC) must be performed in patients with suspected PH to establish the diagnosis and document pulmonary hemodynamics. Before initiation of medical therapy, assessment of acute vasoreactivity (during catheterization) is necessary to determine the appropriate therapy for an individual patient. An acute response is generally defined as a decrease in mean pulmonary arterial pressure of at least 10 mm Hg with the mean pulmonary arterial pressure decreasing to 40 mm Hg or below, accompanied by a normal or high cardiac output. After PAH is diagnosed, disease severity should be assessed in order to accurately determine risk:benefit profiles for various therapeutic options. Useful tools to predict outcome include functional class, exercise capacity, pulmonary hemodynamics, acute vasoreactivity, right ventricular function, as well as brain natriuretic peptide, endothelin-1, uric acid, and troponin levels. Repeating these tests serially on treatment is useful for monitoring the response to a given therapy. Close follow-up at a center specializing in management of PH is recommended, with careful periodic reassessment and adjustment of therapy. (C) 2004 by the American College of Cardiology Foundation.
引用
收藏
页码:40S / 47S
页数:8
相关论文
共 33 条
[21]   Oxygen desaturation on the six-minute walk test and mortality in untreated primary pulmonary hypertension [J].
Paciocco, G ;
Martinez, FJ ;
Bossone, E ;
Pielsticker, E ;
Gillespie, B ;
Rubenfire, M .
EUROPEAN RESPIRATORY JOURNAL, 2001, 17 (04) :647-652
[22]   A comparison of echocardiography and pulmonary artery catheterization for evaluation of pulmonary artery pressures in pregnant patients with suspected pulmonary hypertension [J].
Penning, S ;
Robinson, KD ;
Major, CA ;
Garite, TJ .
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2001, 184 (07) :1568-1570
[23]   Noninvasive diagnosis of suspected severe pulmonary embolism - Transesophageal echocardiography vs spiral CT [J].
Pruszczyk, P ;
Torbicki, A ;
Pacho, R ;
Chlebus, M ;
KuchWocial, A ;
Pruszynski, B ;
Gurba, H .
CHEST, 1997, 112 (03) :722-728
[24]   Nocturnal hypoxemia is common in primary pulmonary hypertension [J].
Rafanan, AL ;
Golish, JA ;
Dinner, DS ;
Hague, LK ;
Arroliga, AC .
CHEST, 2001, 120 (03) :894-899
[25]   ANTINUCLEAR ANTIBODIES IN PRIMARY PULMONARY-HYPERTENSION [J].
RICH, S ;
KIERAS, K ;
HART, K ;
GROVES, BM ;
STOBO, JD ;
BRUNDAGE, BH .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1986, 8 (06) :1307-1311
[26]   PRIMARY PULMONARY-HYPERTENSION - A NATIONAL PROSPECTIVE-STUDY [J].
RICH, S ;
DANTZKER, DR ;
AYRES, SM ;
BERGOFSKY, EH ;
BRUNDAGE, BH ;
DETRE, KM ;
FISHMAN, AP ;
GOLDRING, RM ;
GROVES, BM ;
KOERNER, SK ;
LEVY, PC ;
REID, LM ;
VREIM, CE ;
WILLIAMS, GW .
ANNALS OF INTERNAL MEDICINE, 1987, 107 (02) :216-223
[27]  
RICH S, 2001, CLIN CHEST MED
[28]   Big endothelin-1 and endothelin-1 plasma levels are correlated with the severity of primary pulmonary hypertension [J].
Rubens, C ;
Ewert, R ;
Halank, M ;
Wensel, R ;
Orzechowski, HD ;
Schultheiss, HP ;
Hoeffken, G .
CHEST, 2001, 120 (05) :1562-1569
[29]   Long-term intravenous epoprostenol infusion in primary pulmonary hypertension -: Prognostic factors and survival [J].
Sitbon, O ;
Humbert, M ;
Nunes, H ;
Parent, F ;
Garcia, G ;
Hervé, P ;
Rainisio, M ;
Simonneau, G .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2002, 40 (04) :780-788
[30]   Exercise pathophysiology in patients with primary pulmonary hypertension [J].
Sun, XG ;
Hansen, JE ;
Oudiz, RJ ;
Wasserman, K .
CIRCULATION, 2001, 104 (04) :429-435